2016 FPN Research Symposium

ADVANCES IN NEUROPATHY EMERGING THERAPIES
2016 International Research Symposium

September 7-9, 2016
Palmer House Chicago

 

This important research symposium, entitled “Advances in Neuropathy: Emerging Therapies,”  will address three key areas:

  • The current state and knowledge of Chemo-induced peripheral neuropathy (CIPN); reviewing preclinical studies and outcome measures with a goal of identifying novel drug targets and roadblocks in moving potential therapies to clinical trials.
  • What is in the pipeline? Preclinical drug development for neuropathic pain and peripheral neuropathies.
  • Medicinal use of cannabis in peripheral neuropathies and neuropathic pain. We will combine basic science discussions with clinical topics to stimulate further research on this timely issue. Our goal is to identify area of basic and clinical research to support or refute use of cannabis in peripheral neuropathies and neuropathic pain.

Who will be there?

Our symposium brings together renowned investigators and clinicians from basic and clinical research, young investigators, industry leaders, and representatives from FDA, NIH and NCI.

The format of the meeting provides a forum for open discussion and collaboration between all participants and speakers.

Session #1 CIPN Preclinical Studies & Outcome Measures
Topic #1-Mechanisms of Axonal Degeneration & Preclinical Animal Models in CIPN
Aaron DiAntonio, MD, PhD
Mechanisms of Axon Degeneration in CIPN

Topic #1-Mechanisms of Axonal Degeneration & Preclinical Animal Models in CIPN
Nathan P. Staff, MD, PhD
Mechanisms and Genetics of CIPN

Topic #1-Mechanisms of Axonal Degeneration & Preclinical Animal Models in CIPN
Garry Bennett, PhD
Mitotoxicity as the Cause of CIPN

Topic #1 Mechanisms of Axonal Degeneration and Preclinical Animal Models in CIPN
Moderator: Ahmet Höke, MD, PhD
Panel Discussion & Audience Participation

Topic #2 Clinical & Preclinical Outcome Measures Specific to CIPN
Guido Cavaletti, MD, PhD
Comparison of Otcome Measures in Animal Models & Human Trials  

Topic #2 Clinical & Preclinical Outcome Measures Specific to CIPN
Kathleen Griffith, PhD, MPH, CRNP
CI-PeriNomS: Clinical & Electrophysiological Outcome Measures in CIPN

Topic #2 Clinical & Preclinical Outcome Measures Specific to CIPN
Joanna Brell, MD
CIPN Trials: Oncologists’s Perspective

Topic #2 Clinical & Preclinical Outcome Measures Specific to CIPN
Moderator: A. Gordon Smith, MD
Panel Discussion & Audience Participation

Session#2 – New & Developing Drugs: What’s in the Pipeline
Topic #1 – Whats in the Pipeline-Part 1
Paul Fernyhough, PhD, Bsc
Muscarinic Receptor Antagonism to Treat Peripheral Neuropathy

Topic #1 – Whats in the Pipeline-Part 1
Dan Chiche, MD
NEO6860, a Novel TRPV1 Modality Selective Antagonist: Key in Vitro Data and Results from a Phase I Study

Topic #1 – Whats in the Pipeline-Part 1
Magdalene Moran, PhD
TRPA1 Antagonists for the Treatment of Painful Peripheral Neuropathies

Topic #1 – Whats in the Pipeline-Part 1
Moderator: Roy Freeman, MD
Panel Discussion & Audience Participation

Session #2
Topic #2- What’s in the Pipeline – Part 2
David Fink, MD
Gene Transfer of NT3 to Prevent CIPN

Topic #2- What’s in the Pipeline – Part 2
Mathew Jarpe, PhD
HDAC6 Inhibitor Reverses Established PN Pain in Rodent Models 

Topic #2- What’s in the Pipeline – Part 2
Moderator: Roy Freeman, MD
Panel Discussion & Audience Participation 

Session #3 Cannabis & Neuropathic Pain
Topic #1 – Cannabis and Neuropathic Pain: Basic Science & Clinical Trials
Dr. Daniele Piomelli, PhD,
Basic Science of Cannabis & Analgesia I

Topic #1 – Cannabis and Neuropathic Pain: Basic Science & Clinical Trials
Andrea Hohmann, PhD
Basic Science of Cannabis & Analgesia II

Topic #1 – Cannabis and Neuropathic Pain: Basic Science & Clinical Trials
Mark Wallace, MD
Cannabis in Neuropathic Pain-Focus on HIV PN

Topic #1 – Cannabis and Neuropathic Pain: Basic Science & Clinical Trials
Moderator: Senda Ajroud-Driss
Panel Discussion & Audience Participation

Topic #2 – Medicinal Cannabis: Regulatory, Industry & Medical Perspectives
Marilyn A. Huestis, PhD
Medicinal Use of Cannabis-Regulatory Perspective 

Topic #2 – Medicinal Cannabis: Regulatory, Industry & Medical Perspectives
Nicholas Vita, CEO
Medicinal Use of Cannabis-Industry Perspective

Topic #2 – Medicinal Cannabis: Regulatory, Industry & Medical Perspectives
Mark Ware, MD,  & Andrew Rice, MD
Medicinal Use of Cannabis-Pro/Con

Topic #2 – Medicinal Cannabis: Regulatory, Industry & Medical Perspectives
Moderator: David Simpson, MD
Panel Discussion & Audience Participation